Literature DB >> 7480528

The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rats. Implications for tardive dyskinesia?

O A Andreassen1, H A Jørgensen.   

Abstract

Rats were chronically treated for 4 weeks with three doses (4, 8, 12 mg/kg per day) of the mitochondrial toxin 3-nitropropionic acid (3-NP). The behaviour was videotaped at intervals during and after treatment, and vacuous chewing movements (VCM), a putative analogue to tardive dyskinesia (TD), as well as the general behaviour were scored. During treatment, 3-NP dose-dependently increased VCM and dose-dependently reduced motor activity, which is similar to the behavioural effect of long-term neuroleptic treatment. The results may support the hypothesis that neuroleptic-induced impairment of energy metabolism, a potential excitotoxic mechanism, is involved in the development of VCM in rats and probably TD in humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7480528     DOI: 10.1007/bf02245864

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  15 in total

1.  Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids.

Authors:  E G McGeer; P L McGeer
Journal:  Nature       Date:  1976-10-07       Impact factor: 49.962

Review 2.  Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms.

Authors:  J L Waddington
Journal:  Int Rev Neurobiol       Date:  1989       Impact factor: 3.230

3.  The effect of phenothiazine on the metabolism of liver mitochondria.

Authors:  C H Gallagher; J H Koch; D M Mann
Journal:  Biochem Pharmacol       Date:  1965-05       Impact factor: 5.858

Review 4.  Oxidative damage and mitochondrial decay in aging.

Authors:  M K Shigenaga; T M Hagen; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats.

Authors:  O A Andreassen; H A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

Review 6.  Tardive dyskinesia.

Authors:  D V Jeste; M P Caligiuri
Journal:  Schizophr Bull       Date:  1993       Impact factor: 9.306

7.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.

Authors:  M F Beal; E Brouillet; B G Jenkins; R J Ferrante; N W Kowall; J M Miller; E Storey; R Srivastava; B R Rosen; B T Hyman
Journal:  J Neurosci       Date:  1993-10       Impact factor: 6.167

8.  Haloperidol-induced morphological changes in striatum are associated with glutamate synapses.

Authors:  C K Meshul; R K Stallbaumer; B Taylor; A Janowsky
Journal:  Brain Res       Date:  1994-06-20       Impact factor: 3.252

9.  Systemic 3-nitropropionic acid: long-term effects on locomotor behavior.

Authors:  T K Koutouzis; C V Borlongan; T Scorcia; I Creese; D W Cahill; T B Freeman; P R Sanberg
Journal:  Brain Res       Date:  1994-05-23       Impact factor: 3.252

Review 10.  Oxidative stress, glutamate, and neurodegenerative disorders.

Authors:  J T Coyle; P Puttfarcken
Journal:  Science       Date:  1993-10-29       Impact factor: 47.728

View more
  2 in total

Review 1.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

2.  Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats.

Authors:  O A Andreassen; T O Aamo; H A Jøorgensen
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.